X

Trial Profile

Investigational Product ; Coversin. Phase III Safety and Efficacy in Three-Part, Two-Arm, Randomised Open Label Evaluation in Patients With Paroxysmal Nocturnal Haemoglobinuria (PNH)

Status: Suspended

Phase of Trial: Phase III

Latest Information Update: 30 Jan 2023

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Nomacopan (Primary)
Indications Paroxysmal nocturnal haemoglobinuria
Focus Therapeutic Use
Acronyms CAPSTONE
Sponsors Akari Therapeutics

Most Recent Events

11 Dec 2020 According to a Akari Therapeutics media release, full clinical details on all 19 PNH patients treated with nomacopan will be provided in a manuscript that is currently in preparation.
11 Dec 2020 Results (n=19) derived from COBALT, CAPSTONE and long-term safety study CONSERVE presented in an Akari Therapeutics Media Release.
21 Jan 2020 This trial is completed in Lithuania as per European Clinical Trials Database record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com